Cargando…

Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer

BACKGROUND: Immunotherapy is a promising advance in oncology. Limited information exists regarding the interrelationship between CD47 expression and tumour-associated macrophage-related immuno-microenvironment in patients with non-small cell lung cancer (NSCLC). These factors may predict novel immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yan, Li, Ji, Tong, Bing, Chen, Minjiang, Liu, Xiaoyan, Zhong, Wei, Zhao, Jing, Wang, Mengzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445354/ https://www.ncbi.nlm.nih.gov/pubmed/32830120 http://dx.doi.org/10.1136/esmoopen-2020-000823

Ejemplares similares

Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy
por: Tong, Bing, et al.
Publicado: (2017)

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer
por: Tong, Bing, et al.
Publicado: (2018)

Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer
por: Lang, C., et al.
Publicado: (2022)

Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
por: Zhou, Qing, et al.
Publicado: (2023)

Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
por: Chen, Minjiang, et al.
Publicado: (2019)

Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer
por: Chen, Minjiang, et al.
Publicado: (2021)

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period
por: Ni, Jun, et al.
Publicado: (2021)

Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Tumour-associated CD66b(+) neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer
por: Carus, A, et al.
Publicado: (2013)

Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient
por: Chen, Minjiang, et al.
Publicado: (2021)

Prognostic impact of maximum standardized uptake value on (18)F‐FDG PET/CT imaging of the primary lung lesion on survival in advanced non‐small cell lung cancer: A retrospective study
por: Qiu, Xiaoling, et al.
Publicado: (2021)

Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer
por: Liang, Hongge, et al.
Publicado: (2022)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
por: Liang, Hongge, et al.
Publicado: (2019)

Circulating cytokines associated with clinical outcomes in advanced non‐small cell lung cancer patients who received chemoimmunotherapy
por: Shi, Yuequan, et al.
Publicado: (2021)

Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy
por: Liu, Jia, et al.
Publicado: (2023)

Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis
por: Hendriks, Mark A.J.M., et al.
Publicado: (2021)

Tumour stem cell markers CD133 and CD44 are useful prognostic factors after surgical resection of pancreatic neuroendocrine tumours
por: Sun, Zhonghai, et al.
Publicado: (2020)

Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
por: Orozco-Morales, Mario, et al.
Publicado: (2021)

Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC
por: Petersen, Lars F., et al.
Publicado: (2017)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?
por: Liu, Xiaoyan, et al.
Publicado: (2017)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

ALK‐rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report
por: Xu, Yan, et al.
Publicado: (2018)

CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer
por: Yoshida, Kazumichi, et al.
Publicado: (2015)

Prognostic Utility of CD47 in Cancer of the Uterine Cervix and the Sensitivity of Immunohistochemical Scores
por: Yordanov, Angel, et al.
Publicado: (2022)

CD47 on artificial structures
por: Schütz, Christian
Publicado: (2015)

p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer
por: Fondevila, C, et al.
Publicado: (2004)

Immunotherapy as second‐line treatment and beyond for non‐small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real‐world retrospective analysis
por: Chen, Minjiang, et al.
Publicado: (2020)

CD47-Independent Effects Mediated by the TSP-Derived 4N1K Peptide
por: Leclair, Pascal, et al.
Publicado: (2014)

Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death
por: Chen, Minjiang, et al.
Publicado: (2015)

Small round tumour cells (CD38, CD 79a positive) in the adrenal gland
por: Nigam, L.A., et al.
Publicado: (2017)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
por: Zhao, Jing, et al.
Publicado: (2023)

Costimulation of T Cell Activation by Integrin-associated Protein (CD47) Is an Adhesion-dependent, CD28-independent Signaling Pathway
por: Reinhold, Martina I., et al.
Publicado: (1997)

CD47 Deficiency Attenuates Isoproterenol-Induced Cardiac Remodeling in Mice
por: Zuo, Zhi, et al.
Publicado: (2019)

Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer
por: Sugimura-Nagata, Akane, et al.
Publicado: (2021)

Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients
por: Yuan, Jingping, et al.
Publicado: (2019)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

CD47 antibody inhibits tumor recurrence in a clinical relevant glioblastoma animal model
por: Zhu, Huaiyang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sf62ifkk8i6naes2t4nvn132h4